Trials / Completed
CompletedNCT00269022
Use Of SB-705498 In The Acute Treatment Of Migraine
A Single Blind, Placebo Controlled, Multi-Centre Study to Investigate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of the TRPV1 Antagonist SB-705498 Against the Pain of Acute Migraine.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 70 (planned)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Despite the success of the triptan class of drugs, approximately 60% of patients who take medication at the moderate to severe pain stage of acute migraine, still have pain of mild or greater degree at 2 hrs post dose. SB-705498 is a novel, first in class TRPV1 receptor antagonist under development for the treatment of migraine pain. Preclinical experiments have demonstrated that the TRPV1 receptor is expressed both centrally and peripherally in the trigeminal system and inhibition of TRPV1 with SB-705498 can both prevent and reverse established central sensitisation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SB-705498 |
Timeline
- Start date
- 2006-01-01
- First posted
- 2005-12-23
- Last updated
- 2009-05-18
Locations
4 sites across 4 countries: Australia, Canada, Netherlands, United Kingdom
Source: ClinicalTrials.gov record NCT00269022. Inclusion in this directory is not an endorsement.